New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC
US FDA Decision Expected 1 December
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.